bill before the Senate would cover most uninsured Americans, sav ing thousands of lives each year and putting an end to our status as the only developed country that places so many of its citizens at risk for medical bankruptcy. Moreover, the bills would accom plish this aim while reducing the federal deficit over the next de cade and beyond. They would reform insurance markets, lower administrative costs, increase peo ple's insurance choices, and pro vide "insurance for the insured" by disallowing medical under writing and the exclusion of pre existing conditions. And the Sen ate bill in particular would move us closer to taming the uncon trolled increase in health care spending that threatens to bank rupt our society.
Despite the many reasons to be excited about this legislative breakthrough, skeptics abound. Their criticism is only going to get louder as the bill is debated on the Senate floor over the next few weeks. But the primary criti cisms of the bills are largely un warranted.
One common refrain of oppo nents of reform is that it repre sents a government takeover of health care. But reformers made the key decision at the start of this process to eschew a govern mentdriven redesign of our health care system in favor of building on the private insurance system that works for most Americans.
The primary role of the govern ment in this reform is as a finan cier of the tax credits that indi viduals will use to purchase health insurance from private companies through stateorganized exchang es. In Massachusetts, which passed a similar reform in 2006, private health insurance has expanded dramatically. The public insur ance alternative that is included in the Senate bill simply adds an other competitor -on a level playing field -to the insurance market, and the Congressional Budget Office (CBO) projects that it will enroll only a tiny minority of Americans. 1 A second criticism is that the bills are budget busters. This is simply incorrect. Both bills are completely paid for -indeed, both would reduce the deficit by more than $100 billion over the coming decade. And the CBO es timates that both would reduce the deficit even more in the long run, particularly the Senate bill with its strong costcontainment measures. 1 Some argue that the bills won't reduce the deficit be cause Congress won't follow through on its costreduction plans, as it has failed to do with the sustainablegrowthrate pro gram for Medicare's physician payments. But this one example has been ridiculously overused, given the sizable Medicare reduc tions that Congress has made in the past; the proposed reduction in Medicare spending is less than half of the percentage reduction enacted in 1997, for example. 2 To oppose a bill because of a mis placed fear that the government cannot keep its promises is es sentially to shut down the legis lative process.
In addition, some claim that the bills are an attack on Medi care and argue that it is unfair to pay for expanded coverage by reducing overpayments to hospi tals and to the private insurers that offer Medicare Advantage plans. It's ironic that the people taking this position are often the same ones who make the first criticism (Medicare, after all, is a governmentrun insurance sys tem) or the second (if the govern ment will never follow through on its promises, we needn't worry about reduced payments). In any case, there is substantial evidence that reducing these overpayments will not harm the health of Medi care patients -just the pocket books of those who profit from them. This reform would simply use market bidding to set the re imbursement rate for Medicare Advantage plans, rather than set ting administrative prices, which have traditionally been much too high; and it would reduce pay ments to hospitals by a small per centage, while tying them to out come measures. Moreover, the dollars that are raised will save thousands of lives each year by increasing insurance coverage among the nonelderly.
The bills are also said to im pose unaffordable mandates on individuals. Without the individ ual mandate, fundamental insur ancemarket reform is impossi ble and we cannot cover the majority of the uninsured. But an individual mandate without finan cial assistance for lowincome families is unethical. Both bills contain billions of dollars in sub sidies to help families pay for health insurance -and an ex clusion from the mandate for families that still find coverage unaffordable. Rather than impos ing an unaffordable mandate, these bills would finally guaran tee that almost all Americans could find affordable insurance.
Some argue that the bills would harm the privately insured. But although a primary focus of reform has been on helping the uninsured, the bills also deliver enormous benefits to the private ly insured. Americans who previ ously purchased insurance in an overpriced, unpredictable non group insurance market will have the ease and certainty of buying through an organized market place where insurance loads are lower, prices do not vary accord ing to health status, and preexist ing conditions cannot be exclud ed from coverage. CBO data show that the average enrollee in the new exchanges will either pay substantially less or obtain more generous coverage than the aver age person in today's nongroup insurance market. 3 Employees of small businesses that enroll in the exchange will also benefit from the lower prices and wide variety of health plan choices available to larger groups, and their employers will benefit from a smallbusiness tax credit. Em ployees in large businesses will benefit from a shifting of their employers' money from excessive ly expensive insurance to increased wages. Most important for the insured, this reform will start us down the road to fundamental cost control, which will reduce costs for everyone in the long run.
Some critics also argue, how ever, that the bills don't do enough to control costs. This argument ignores fundamental reforms in the Senate bill in par ticular, which includes a four pronged attack on health care costs. First, it imposes a tax on highcost insurance plans that will put pressure on insurers and employers to keep the cost of in surance down, while delivering $234 billion in wage income to workers over the next decade. 4 Second, it includes funds and a structure for comparativeeffec tiveness research that will pro vide the information necessary to guide our health care system to ward care that works and away from care that doesn't. Third, it establishes a Medicare advisory board with the power to set rates (subject to an upordown vote by Congress) if costs grow too rapidly. Finally, it sets up an in novation center within the Cen ters for Medicare and Medicaid Services and launches pilot proj ects to explore alternative reim bursement and organizational structures that could transform the delivery of care.
This argument also misses the important point that universal coverage is vital for cost control. Most of the reforms that are aimed at controlling costs work through changes in the ways in which insurers reimburse and or ganize care. These changes can't work if an evergrowing propor tion of our population lacks in surance. Moreover, as we have seen in Massachusetts, dealing with the problem of the unin sured allows policymakers to fo cus more singlemindedly on cost control: after our universalcov erage law passed, the state moved aggressively to set up a costcon trol commission that recommend ed important changes in provider reimbursement. 5 The current bills are not per fect. The Senate bill has a man date that's too weak and doesn't provide generous enough insur ance to lowincome individuals, and the House bill doesn't do enough to control costs. Never theless, passage of a hybrid of these bills would be a major ac complishment and a turning point for our dysfunctional health care system. We should constructive ly support Congress's efforts to create a combined bill, rather than leveling unsubstantiated criticisms from the sidelines.
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reast cancer is the most common cancer in women in the United States, with more than 190,000 women receiving a diagnosis of invasive disease an nually 1 and more than 40,000 dying of breast cancer each year. Worldwide, more than 1 million women are diagnosed with breast cancer and more than 500,000 die from it each year. 2 During the past two decades, there have been modest but real decreases in breastcancer mortality that have been attributed to improvements in early detection and treatment. It is in this context that the re cent controversy surrounding the optimal approach to breastcancer screening should be considered.
On November 16, 2009, the U.S. Preventive Services Task Force (USPSTF) released updated rec ommendations for breastcancer screening, 3 informed by addition al followup from previous studies and a new study focused on sta tistical modeling. 4,5 The two most substantive and controversial rec ommendations were that mam mography be eliminated as a "standard test" for women 40 to 49 years of age and that mammog raphy be performed biennially rather than annually in women from 50 to 74 years of age.
The rationale for the changes was clearly delineated by the task force. Although mammography decreases breastcancer mortality among women in their 40s, the absolute benefit is smaller than among older women, because the disease is less common in the younger age group. Younger women are also more likely to have false positive results, which lead to additional testing, anxiety, and psychological distress. For women in their 40s who are not at in creased risk for breast cancer, the USPSTF recommends that the ben efits of mammography be care fully weighed against the poten tial adverse consequences.
The recommendation for bien nial rather than annual screen ing was based on the modeling study and crossstudy comparisons suggesting that more frequent screening is not associated with better outcomes. Moreover, the panel concluded that the rate of false positive results appears to be much lower with biennial mam mography.
The updated recommendations sparked substantial controversy and have had a polarizing effect in the breastcancer community. There has been confusion, fear, and anger on the part of patients with breast cancer, their families, and women's health advocates. The intensity of the controversy
